<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477227</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477227</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Depression and systemic lupus erythematosus: a systematic review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Palagini</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477227">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313477227"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mosca</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477227">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tani</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477227">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gemignani</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313477227">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mauri</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477227">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bombardieri</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477227">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313477227"><label>1</label>Psychiatry Unit, Department of Neuroscience, University of Pisa, Italy</aff>
<aff id="aff2-0961203313477227"><label>2</label>Rheumatology Unit, Department of Internal Medicine, University of Pisa, Italy</aff>
<aff id="aff3-0961203313477227"><label>3</label>Department of Physiological Sciences, University of Pisa, Italy Extreme Centre, Italy</aff>
<author-notes>
<corresp id="corresp1-0961203313477227">Laura Palagini, Psychiatric Unit, Department of Neuroscience, University of Pisa, Via Roma, 67, 56126, Pisa, Italy. Email: <email>lpalagini@tiscali.it</email>, <email>l.palagini@ao-pisa.toscana.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>409</fpage>
<lpage>416</lpage>
<history>
<date date-type="received"><day>7</day><month>9</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec14-0961203313477227"><title>Objective</title>
<p>Systemic lupus erythematosus (SLE) is a chronic, relapsing–remitting autoimmune disorder that involves multiple organ systems including the central nervous system. Among the items included in the nomenclature for neuropsychiatric SLE, mood disorders have been identified. The aim of this paper is to review the clinical and psychobiological relationship between depression and SLE.</p>
</sec>
<sec id="sec15-0961203313477227"><title>Method</title>
<p>We performed a systematic search of MEDLINE, EMBASE, PsychINFO, using MeSH headings and keywords for ‘depression’ and ‘SLE’.</p>
</sec>
<sec id="sec16-0961203313477227"><title>Results</title>
<p>Seventeen studies reported depressive disorders, with prevalence rates in the range 17–75%. Three studies reported the most frequent symptoms, which may be represented by fatigue, weakness, somatic disorders and sleep disorders. Suicide ideation was much higher than in the general population. Nine studies analysed the relationship to SLE disease activity. The results of the available literature are contradictory. Psychobiological hypotheses have been considered in 13 studies. Among the psychobiological hypotheses which might underline the plausibility of their relationship, ‘psychosocial factors’ were the most frequently reported.</p>
</sec>
<sec id="sec17-0961203313477227"><title>Conclusions</title>
<p>Differences in assessment techniques appear to be the main explanation for the variability in findings and important methodological limitations are present in the available literature to definitively point to the prevalence of depression, type of depression and most prevalent symptoms. To date, the relationship between depression and SLE disease activity also appears controversial. Methodological limitations are present in the available literature and it would be necessary to develop evidence-based guidelines to improve the diagnosis of depression in SLE. Identification of SLE-specific biomarkers of depression also has high priority.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Depression</kwd>
<kwd>depressive disorders</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>biomarkers</kwd>
<kwd>brain imaging</kwd>
<kwd>magnetic resonance</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>edited-state</meta-name>
<meta-value>corrected-proof</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313477227" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a chronic, relapsing–remitting autoimmune disorder that is most prevalent in women and involves multiple organ systems<sup><xref ref-type="bibr" rid="bibr1-0961203313477227">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr5-0961203313477227">5</xref></sup> including the central nervous system (CNS). The most prevalent manifestations are arthritis, cutaneous manifestations, glomerulonephritis and vasculitis.<sup><xref ref-type="bibr" rid="bibr1-0961203313477227">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr5-0961203313477227">5</xref></sup></p>
<p>CNS involvement with its rich symptomatology belongs to unrecognized and misunderstood aspects of SLE.<sup><xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref></sup> However, neuropsychiatric symptoms often precede other clinical manifestations and rarely lead to diagnosis of SLE.<sup><xref ref-type="bibr" rid="bibr7-0961203313477227">7</xref></sup> More than 100 years ago, Kaposi reported that mental changes might be associated with SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203313477227">8</xref></sup> Subsequently the classification and nomenclature of nervous system disorders in SLE have evolved, from the first attempt proposed in 1979<sup><xref ref-type="bibr" rid="bibr9-0961203313477227">9</xref></sup> to the current classification by the American College of Rheumatology.<sup><xref ref-type="bibr" rid="bibr10-0961203313477227">10</xref></sup></p>
<p>In 1999, the American College of Rheumatology developed a nomenclature system for 19 neuropsychiatric syndromes in SLE: the neuropsychiatric SLE (NPSLE).<sup><xref ref-type="bibr" rid="bibr10-0961203313477227">10</xref></sup> This classification recognizes five groups of neuropsychiatric disorders: mood disorder, anxiety disorder, cognitive dysfunction, psychosis and acute confusional state.<sup><xref ref-type="bibr" rid="bibr10-0961203313477227">10</xref></sup></p>
<p>According to this classification, a prevalence of NPSLE ranging between 14% and 89% of patients has been reported in the literature.<sup><xref ref-type="bibr" rid="bibr5-0961203313477227">5</xref>,<xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref></sup></p>
<p>Among NPSLE manifestations, depression is one of the most frequent disorders observed in patients with SLE. Studies cite a broad range of prevalence rates of depression ranging from 17% to 75%,<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup> which is much higher than in the general population. Some studies have found that an increase in SLE disease activity might lead to an increased vulnerability for depressive disorders.<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr27-0961203313477227">27</xref></sup> The nature of the clinical and psychobiological relationship between depressive disorders and SLE is actually poorly understood.</p>
<p>Since other neuropsychiatric disorders in SLE are well described elsewhere,<sup><xref ref-type="bibr" rid="bibr5-0961203313477227">5</xref>,<xref ref-type="bibr" rid="bibr28-0961203313477227">28</xref></sup> the primary aim of this article was to systematically review the clinical evidences of the association between depressive disorders and SLE. The second aim was to review the psychobiological hypotheses underlining the plausibility of their relationship.</p>
</sec>
<sec id="sec2-0961203313477227" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203313477227"><title>Search strategy</title>
<p>We performed a systematic search of MEDLINE, EMBASE and PsychINFO. The initial search was conducted in November 2011 with a final search in May 2012. The search strategies used MeSH headings and keywords ‘depression’ or ‘psychiatric disorders’ or ‘mood disorders’ or ‘depressive symptoms’ or ‘sadness’ or ‘systemic lupus erythematosus’ or ‘brain imaging’ or ‘magnetic resonance’ or ‘biomarkers’. The searches were limited to English language studies involving adults; studies of children were excluded from the analysis.</p>
</sec>
<sec id="sec4-0961203313477227"><title>Inclusion and exclusion criteria</title>
<p>Studies were included if they: 1) involved adult participants aged over 18 years; 2) were prospective studies, were cross-sectional studies, were with control group; 3) systematic reviews or meta-analyses; 4) analysed the relationship between depression and SLE; 5) were published between 1960 and May 2012.</p>
<p>Studies were excluded if they: 1) did not control for confounding factors in the relationship between depression and SLE (CNS manifestations, such as neurologic or psychotic symptoms, the effects of stressful life events, severity of previous depressive episodes) and analysing data stratified by race and age; 2) were not available in full text; or 3) were not available in English.</p>
</sec>
</sec>
<sec id="sec5-0961203313477227" sec-type="results"><title>Results</title>
<sec id="sec6-0961203313477227"><title>Depression and SLE: clinical evidences</title>
<sec id="sec7-0961203313477227"><title>Prevalence</title>
<p>Several studies have found that depression is highly prevalent in SLE. Among the articles initially identified, 17 studies met the inclusion criteria.<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr15-0961203313477227">15</xref>,<xref ref-type="bibr" rid="bibr17-0961203313477227">17</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr19-0961203313477227">19</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref>,<xref ref-type="bibr" rid="bibr29-0961203313477227">29</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr35-0961203313477227">35</xref></sup> Sample sizes ranged from 25 to 326 subjects: all studies were of adult subjects, nine both male and female subjects, three only female subjects. <xref ref-type="table" rid="table1-0961203313477227">Table 1</xref> summarizes the studies from 1972. Differences in assessment techniques appeared to be the main source of the variability in findings; moreover, prevalence of depression in SLE may vary across different populations.
<table-wrap id="table1-0961203313477227" position="float"><label>Table 1</label><caption><p>Prevalence rates of depressive disorders in systemic lupus erythematosus</p></caption>
<graphic alternate-form-of="table1-0961203313477227" xlink:href="10.1177_0961203313477227-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Authors</th>
<th>Study design</th>
<th>Study size</th>
<th>Study population</th>
<th>Symptom assessment</th>
<th>Depression %</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Ganz et al.<sup><xref ref-type="bibr" rid="bibr29-0961203313477227">29</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>68</td>
<td>SLE Adult 16–72 years USA</td>
<td>Structured clinical interview</td>
<td>51</td>
</tr>
<tr>
<td>Liang et al.<sup><xref ref-type="bibr" rid="bibr30-0961203313477227">30</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>76</td>
<td>SLE Adult Canada</td>
<td>Minnesota Multiphasic Personality Inventory</td>
<td>41</td>
</tr>
<tr>
<td>Lim et al.<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>40</td>
<td>SLE Adult UK</td>
<td>Structured clinical interview</td>
<td>Major depression 20</td>
</tr>
<tr>
<td>Lim et al.<sup><xref ref-type="bibr" rid="bibr31-0961203313477227">31</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>30</td>
<td>SLE Adult Japan</td>
<td>Interview + psychological test</td>
<td>Major depression 33</td>
</tr>
<tr>
<td>Magner<sup><xref ref-type="bibr" rid="bibr32-0961203313477227">32</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>25</td>
<td>SLE Adult Africa</td>
<td>Present State Examination</td>
<td>Neurotic depression 40</td>
</tr>
<tr>
<td>Wekking<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref></sup></td>
<td>Review</td>
<td>19 studies (six cross-sectional)</td>
<td>SLE Adult</td>
<td/>
<td>2–54</td>
</tr>
<tr>
<td>Iverson<sup><xref ref-type="bibr" rid="bibr12-0961203313477227">12</xref></sup></td>
<td>Review</td>
<td/>
<td>SLE Adult</td>
<td/>
<td>Serious methodological limitations; point prevalences not available</td>
</tr>
<tr>
<td>Miguel et al.<sup><xref ref-type="bibr" rid="bibr14-0961203313477227">14</xref></sup></td>
<td>Cross-sectional Control group Healthy subjects</td>
<td>43</td>
<td>SLE Adult Brazil</td>
<td>Structured clinical interview</td>
<td>44</td>
</tr>
<tr>
<td>Ainiala et al.<sup><xref ref-type="bibr" rid="bibr17-0961203313477227">17</xref></sup></td>
<td>Cross-sectional Population-based</td>
<td>46</td>
<td>SLE Adult Finland</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>Mild depression 43</td>
</tr>
<tr>
<td>Brey et al.<sup><xref ref-type="bibr" rid="bibr18-0961203313477227">18</xref></sup></td>
<td>Cross-sectional</td>
<td>128</td>
<td>SLE Adult USA</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>Major depressive-like 28 Mood disorder with depressive features 19 Mood disorder with manic features 3, 3 Mood disorder with mixed features 1, 1</td>
</tr>
<tr>
<td>Sanna et al.<sup><xref ref-type="bibr" rid="bibr19-0961203313477227">19</xref></sup></td>
<td>Cross-sectional</td>
<td>323</td>
<td>SLE Adult UK</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>Mood disorders 16, 7</td>
</tr>
<tr>
<td>Nery et al.<sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup></td>
<td>Cross-sectional</td>
<td>71</td>
<td>SLE Adult Women Brazil</td>
<td>Structured Clinical Interview for DSM-IV (SCID)</td>
<td>Mood disorders Lifetime 26.8</td>
</tr>
<tr>
<td>Stromberg et al.<sup><xref ref-type="bibr" rid="bibr33-0961203313477227">33</xref></sup></td>
<td>Cross-sectional</td>
<td>155</td>
<td>SLE Adult women Sweden</td>
<td>Beck Depression Inventory</td>
<td>22.4</td>
</tr>
<tr>
<td>Bachen et al.<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup></td>
<td>Cross-sectional</td>
<td>326</td>
<td>SLE Adult women USA</td>
<td>Telephone Composite International Diagnostic Interview according to DSM-IV</td>
<td>Major depression 42.4 Bipolar I depression 4.9 Dysthymic disorders 2.9</td>
</tr>
<tr>
<td>Hawro et al.<sup><xref ref-type="bibr" rid="bibr34-0961203313477227">34</xref></sup></td>
<td>Cross-sectional No control group</td>
<td>52</td>
<td>SLE Adult Poland</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>Depressive disorders 11.54</td>
</tr>
<tr>
<td>Meszaros et al.<sup><xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref></sup></td>
<td>Review</td>
<td>18 studies</td>
<td>SLE Adult</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>39</td>
</tr>
<tr>
<td>Zakeri et al.<sup><xref ref-type="bibr" rid="bibr35-0961203313477227">35</xref></sup></td>
<td>Cross-sectional No control group</td>
<td>85</td>
<td>SLE Adult Iran</td>
<td>Beck Depression Inventory</td>
<td>60</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313477227"><p>SLE: systemic lupus erythematosus; NPSLE: neuropsychiatric SLE; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Generic diagnosis of depression ranges from 2% to 60%, a diagnosis of major depression ranges from 20% to 47% and diagnosis of mood disorders ranges from 16.7% to 26.8%. Serious methodological limitations are present in the available literature and definitive point prevalence is difficult to determine. However, recent estimates suggest that point prevalence rates of clinically significant symptoms and lifetime incidence of major depressive disorder might occur in approximately half of patients with SLE,<sup><xref ref-type="bibr" rid="bibr18-0961203313477227">18</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup> which is, in any case, much higher than in the general population. Methodological guidelines are needed to study point prevalence rates of depression and its different forms – major depression, unipolar/bipolar depression, depressive symptoms – in SLE.</p>
</sec>
<sec id="sec8-0961203313477227"><title>Subset of depressive symptoms</title>
<p>The most common depressive symptoms reported in SLE are summarized in <xref ref-type="table" rid="table2-0961203313477227">Table 2</xref>. Among the articles initially identified, three studies met the inclusion criteria.<sup><xref ref-type="bibr" rid="bibr12-0961203313477227">12</xref>,<xref ref-type="bibr" rid="bibr35-0961203313477227">35</xref>,<xref ref-type="bibr" rid="bibr36-0961203313477227">36</xref></sup> Sample sizes ranged from 85 to 203 subjects: all studies involved adults, both male and female. The depressive symptoms most frequently reported were fatigue and weakness (88–90%), which might be closely correlated to the core symptoms of SLE. In addition, irritability (82.3%), somatic preoccupation (76%) and trouble falling asleep (70%) were also frequently reported. Sadness has been reported from 29% to 77%.
<table-wrap id="table2-0961203313477227" position="float"><label>Table 2</label><caption><p>Prevalence rates of depressive symptoms in SLE</p></caption>
<graphic alternate-form-of="table2-0961203313477227" xlink:href="10.1177_0961203313477227-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Authors</th>
<th>Study design</th>
<th>Study size</th>
<th>Study population</th>
<th>Symptoms assessment</th>
<th>Depressive symptoms %</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Iverson<sup><xref ref-type="bibr" rid="bibr12-0961203313477227">12</xref></sup></td>
<td>Cross-sectional Control group</td>
<td>103</td>
<td>SLE Adult Canada</td>
<td>British Columbia Inventory Beck Depression Inventory</td>
<td>Fatigue 90.2 Trouble failing asleep 70.7 Cognitive difficulty 61 Psychomotor slowing 58.5 Sadness 29.3</td>
</tr>
<tr>
<td>Zakeri et al.<sup><xref ref-type="bibr" rid="bibr35-0961203313477227">35</xref></sup></td>
<td>Cross-sectional No control group</td>
<td>85</td>
<td>SLE Adult Iran</td>
<td>Beck Depression Inventory</td>
<td>Fatigue and weakness 88.2 Irritability 82.3 Sadness 77.6 Somatic preoccupation 76.4 Weight loss 34.1 Low level of energy 28.2 Suicide ideation 10.5</td>
</tr>
<tr>
<td>Xie et al.<sup><xref ref-type="bibr" rid="bibr36-0961203313477227">36</xref></sup></td>
<td>Cross-sectional</td>
<td>285</td>
<td>SLE Adult China</td>
<td>Beck Depression Inventory</td>
<td>Suicide ideation 34.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203313477227"><p>SLE: systemic lupus erythematosus</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Among the studies initially identified, only two evaluated prevalence of suicide ideation; prevalence rates range from 10% to 34%, which is much higher than in the general population.</p>
<p>More studies are needed to identify the most common subset of depressive symptoms in SLE and methodological guidelines are needed to study this aspect. Few studies and methodological limitations are present in the available literature and a definitive subset of depressive symptoms is difficult to determine. Moreover, very few studies in the available literature include the evaluation of suicide ideation even if prevalence rates in SLE patients are higher than in the general population.</p>
</sec>
<sec id="sec9-0961203313477227"><title>Relation to SLE disease activity</title>
<p>The results are summarized in <xref ref-type="table" rid="table3-0961203313477227">Tables 3</xref> and <xref ref-type="table" rid="table4-0961203313477227">4</xref>. Among the literature initially identified, nine met the inclusion criteria. Sample sizes ranged from 20 to 349 subjects and all studies involved male and female adult subjects. The results in the available literature are contradictory. Five studies suggested a relation between depression and SLE disease activity.<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref></sup> Severity of depression may increase with more severe disease course and, vice versa, SLE disease activity may be related to the presence of depression.<sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup> The findings in three studies indicate that SLE disease activity may increase vulnerability to depression.<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref>,<xref ref-type="bibr" rid="bibr24-0961203313477227">24</xref></sup> Indeed, these findings are not confirmed in the other studies, that is, no relation has been found between disease activity and depression.<sup><xref ref-type="bibr" rid="bibr12-0961203313477227">12</xref>,<xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref>,<xref ref-type="bibr" rid="bibr27-0961203313477227">27</xref></sup> Few studies and methodological limitations are present in the available literature and the results remain contradictory.
<table-wrap id="table3-0961203313477227" position="float"><label>Table 3</label><caption><p>Relation between depression and SLE disease activity</p></caption>
<graphic alternate-form-of="table3-0961203313477227" xlink:href="10.1177_0961203313477227-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Authors</th>
<th>Study design</th>
<th>Study size</th>
<th>Study population</th>
<th>Symptoms assessment</th>
<th>Relation Depression–SLE disease activity</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Wekking<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref></sup></td>
<td>Review</td>
<td>19 studies (6 cross-sectional)</td>
<td>SLE Adult</td>
<td/>
<td>Contradictory</td>
</tr>
<tr>
<td>Utset et al.<sup><xref ref-type="bibr" rid="bibr24-0961203313477227">24</xref></sup></td>
<td>Cross-sectional</td>
<td>349</td>
<td>SLE Adult USA</td>
<td>Structured clinical interview</td>
<td>Depressive symptoms are related to disease activity</td>
</tr>
<tr>
<td>Shortall et al.<sup><xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref></sup></td>
<td>Cross-sectional</td>
<td>80</td>
<td>SLE Adult UK</td>
<td>Symptom questionnaire</td>
<td>Mood and mood disorders are not related to disease activity</td>
</tr>
<tr>
<td>Walker et al.<sup><xref ref-type="bibr" rid="bibr26-0961203313477227">26</xref></sup></td>
<td>Cross-sectional Longitudinal</td>
<td>80</td>
<td>SLE Adult USA</td>
<td>Symptom questionnaire</td>
<td>Mood states are related to disease activity</td>
</tr>
<tr>
<td>Segui et al.<sup><xref ref-type="bibr" rid="bibr27-0961203313477227">27</xref></sup></td>
<td>Cross-sectional Longitudinal</td>
<td>20</td>
<td>SLE Adult women Spain</td>
<td>Beck Depression Inventory</td>
<td>No significant differences in the grade of depression during inactive and active stages of the disease</td>
</tr>
<tr>
<td>Bachen et al.<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup></td>
<td>Cross-sectional</td>
<td>326</td>
<td>SLE Adult Women USA</td>
<td>Telephone Composite International Diagnostic Interview according to DSM-IV</td>
<td>Disease activity contributes to psychiatric symptomatology</td>
</tr>
<tr>
<td>Nery et al.<sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup></td>
<td>Cross-sectional</td>
<td>71</td>
<td>SLE Adult women Brazil</td>
<td>Structured Clinical Interview for DSM-IV (SCID)</td>
<td>Severity of depression might increase with more severe disease course and, vice versa, SLE disease activity might be related to the presence of depression</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203313477227"><p>SLE: systemic lupus erythematosus; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0961203313477227" position="float"><label>Table 4</label><caption><p>SLE disease activity and vulnerability for depression</p></caption>
<graphic alternate-form-of="table4-0961203313477227" xlink:href="10.1177_0961203313477227-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Authors</th>
<th>Study design</th>
<th>Study size</th>
<th>Study population</th>
<th>Symptoms assessment</th>
<th>SLE disease activity and vulnerability for depression</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Wekking<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref></sup></td>
<td>Review</td>
<td>19 studies (six cross-sectional)</td>
<td>SLE Adult</td>
<td/>
<td>Depressive symptoms might be adjustment reactions to the stresses of the disease</td>
</tr>
<tr>
<td>Iverson<sup><xref ref-type="bibr" rid="bibr12-0961203313477227">12</xref></sup></td>
<td>Review</td>
<td/>
<td>SLE Adult</td>
<td/>
<td>No conclusive evidence that the disease causes psychiatric dysfunction</td>
</tr>
<tr>
<td>Miguel et al.<sup><xref ref-type="bibr" rid="bibr14-0961203313477227">14</xref></sup></td>
<td>Cross-sectional Control group Healthy subjects</td>
<td>43</td>
<td>SLE Adult Brazil</td>
<td>Structured clinical interview</td>
<td>Increased</td>
</tr>
<tr>
<td>Utset et al.<sup><xref ref-type="bibr" rid="bibr24-0961203313477227">24</xref></sup></td>
<td>Cross-sectional</td>
<td>349</td>
<td>SLE Adult USA</td>
<td>Structured clinical interview</td>
<td>Increased</td>
</tr>
<tr>
<td>Shortall et al.<sup><xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref></sup></td>
<td>Cross-sectional</td>
<td>80</td>
<td>SLE Adult UK</td>
<td>Structured clinical interview</td>
<td>Not increased</td>
</tr>
<tr>
<td>Bachen et al.<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup></td>
<td>Cross-sectional</td>
<td>326</td>
<td>SLE Adult women USA</td>
<td>Telephone Composite International Diagnostic Interview according to DSM-IV</td>
<td>Self-reported disease activity but not disease severity predicted lifetime diagnoses of major depression</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203313477227"><p>SLE: systemic lupus erythematosus; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
</sec>
<sec id="sec10-0961203313477227"><title>Depression and SLE: psychobiological hypotheses</title>
<p>The results are summarized in <xref ref-type="table" rid="table5-0961203313477227">Table 5</xref>. Among the literature initially identified, 13 studies met the inclusion criteria.<sup><xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref>,<xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref>,<xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref>,<xref ref-type="bibr" rid="bibr27-0961203313477227">27</xref>,<xref ref-type="bibr" rid="bibr32-0961203313477227">32</xref>,<xref ref-type="bibr" rid="bibr37-0961203313477227">37</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr40-0961203313477227">40</xref></sup> Sample sizes ranged from 20 to 349 subjects; all studies involved male and female adult subjects. The results of the available literature are again contradictory. ‘Psychosocial factors’ have been considered the most frequent possible cause of depression in SLE, including environmental factors, and psychological reaction to both SLE disease and social stress.
<table-wrap id="table5-0961203313477227" position="float"><label>Tables 5</label><caption><p>SLE and depression: psychobiological hypotheses</p></caption>
<graphic alternate-form-of="table5-0961203313477227" xlink:href="10.1177_0961203313477227-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Authors</th>
<th>Study design</th>
<th>Study size</th>
<th>Study population</th>
<th>Symptoms assessment</th>
<th>Hypothesis of depression in SLE</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Lim et al.<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>40</td>
<td>SLE Adult UK</td>
<td>Structured clinical interview</td>
<td>Environmental factors: closely related to affective disturbances Clinical/laboratory indices of disease activity: no correlation with psychiatric disorders Brain magnetic resonance: no relation between brain abnormalities and psychiatric disorders</td>
</tr>
<tr>
<td>Magner<sup><xref ref-type="bibr" rid="bibr32-0961203313477227">32</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis</td>
<td>25</td>
<td>SLE Adult Africa</td>
<td>Present state examination</td>
<td>Steroid usage: no contribution to psychiatric symptoms Psychosocial factors: positively related to psychiatric morbidity</td>
</tr>
<tr>
<td>Schneebaum<sup><xref ref-type="bibr" rid="bibr37-0961203313477227">37</xref></sup></td>
<td>Cross-sectional Control group Rheumatoid arthritis Healthy subjects</td>
<td>269</td>
<td>SLE Adult USA</td>
<td>Structured clinical interview</td>
<td>Autoimmune mechanism: elevated levels of auto-antibodies to the C-terminal region of ribosomal P proteins are specific marker for SLE, and are associated with severity of depression</td>
</tr>
<tr>
<td>Wekking<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref></sup></td>
<td>Review</td>
<td>19 studies (six cross-sectional)</td>
<td>SLE Adult</td>
<td/>
<td>Depressive symptoms might be adjustment reactions to the stresses of the disease Steroid usage: contradictory relation with psychiatric disorders Psychosocial factors: positively related to psychiatric morbidity</td>
</tr>
<tr>
<td>Utset et al.<sup><xref ref-type="bibr" rid="bibr24-0961203313477227">24</xref></sup></td>
<td>Cross-sectional</td>
<td>349</td>
<td>SLE Adult USA</td>
<td>Structured clinical interview</td>
<td>Depression does not occur purely as a response to social stresses Autoimmune mechanism: depression might be manifestation of autoimmune disease</td>
</tr>
<tr>
<td>Shortall<sup><xref ref-type="bibr" rid="bibr25-0961203313477227">25</xref></sup></td>
<td>Cross-sectional</td>
<td>80</td>
<td>SLE Adult UK</td>
<td>Structured clinical interview</td>
<td>– psychosocial factors: positively related to psychiatric morbidity</td>
</tr>
<tr>
<td>Segui et al.<sup><xref ref-type="bibr" rid="bibr27-0961203313477227">27</xref></sup></td>
<td>Cross-sectional Longitudinal</td>
<td>20</td>
<td>SLE Adult women Spain</td>
<td>Beck Depression Inventory</td>
<td>Depression is a reaction to the psychological impact of disease</td>
</tr>
<tr>
<td>Eber<sup><xref ref-type="bibr" rid="bibr38-0961203313477227">38</xref></sup></td>
<td>Review</td>
<td/>
<td>SLE Adult</td>
<td/>
<td>Autoimmune mechanism: controversial role of anti-P antibodies</td>
</tr>
<tr>
<td>Zandman-Goddard et al.<sup><xref ref-type="bibr" rid="bibr39-0961203313477227">39</xref></sup></td>
<td>Review</td>
<td/>
<td>SLE Adult</td>
<td/>
<td>Autoimmune mechanism: depression is associated with many brain specific and systemic auto-antibodies</td>
</tr>
<tr>
<td>Nery et al.<sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref></sup></td>
<td>Cross-sectional</td>
<td>71</td>
<td>SLE Adult women Brazil</td>
<td>Structured Clinical Interview for DSM-IV(SCID)</td>
<td>Clinical/laboratory indices of disease activity: no correlation with psychiatric disorders Autoimmune mechanism: no role of P antibodies</td>
</tr>
<tr>
<td>Bachen et al.<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup></td>
<td>Cross-sectional</td>
<td>326</td>
<td>SLE Adult women USA</td>
<td>Telephone Composite International Diagnostic Interview DSM-IV</td>
<td>Psychosocial factors: positively related to psychiatric morbidity Autoimmune mechanism: antineuronal and anti-pahospholipid antibodies related to depression Immunological mechanism: Pro-inflammatory cytokines related to depression</td>
</tr>
<tr>
<td>Giovacchini et al.<sup><xref ref-type="bibr" rid="bibr40-0961203313477227">40</xref></sup></td>
<td>Cross-sectional</td>
<td>30</td>
<td>SLE Adult women</td>
<td>SPECT</td>
<td>Depressed patients with SLE have CBF reductions in discrete temporal and frontal regions that may account for depressive symptoms</td>
</tr>
<tr>
<td>Meszaros et al.<sup><xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref></sup></td>
<td>Review</td>
<td>18 studies</td>
<td>SLE Adult</td>
<td>American College of Rheumatology case definitions for NPSLE</td>
<td>Genetic and environmental factors (e.g. ultraviolet light, retroviruses, and medications) may play a role in the pathogenesis. Depression is a reaction to the psychological impact of disease Biomarkers currently are non-specific for neuropsychiatric disease</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203313477227"><p>SLE: systemic lupus erythematosus; NPSLE: neuropsychiatric SLE; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; CBF: cerebral blood flow</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Whether major depression in active SLE is a CNS manifestation related to the disease, mediated by an autoimmune mechanism, warrants further research.</p>
<p>Seven studies examined the possible role of autoimmune mechanism.<sup><xref ref-type="bibr" rid="bibr6-0961203313477227">6</xref>,<xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr24-0961203313477227">24</xref>,<xref ref-type="bibr" rid="bibr37-0961203313477227">37</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr39-0961203313477227">39</xref></sup> Principally anti-P antibodies have been identified as potentially involved in the pathogenesis of NPSLE in some studies.<sup><xref ref-type="bibr" rid="bibr23-0961203313477227">23</xref>,<xref ref-type="bibr" rid="bibr38-0961203313477227">38</xref></sup> Other autoantibody specificities have been examined, such as brain specific and systemic<sup><xref ref-type="bibr" rid="bibr39-0961203313477227">39</xref></sup> or antineuronal and antiphospholipid antibodies,<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup> but contrasting data have been obtained which require further research. Other immunological mechanisms involving proinflammatory cytokines have been hypothesized<sup><xref ref-type="bibr" rid="bibr22-0961203313477227">22</xref></sup> but, to date, these hypotheses have not been confirmed. Currently, we may conclude that no specific biomarkers for depression in SLE are available. The contribution of steroid usage to depression in SLE is also controversial.<sup><xref ref-type="bibr" rid="bibr13-0961203313477227">13</xref>,<xref ref-type="bibr" rid="bibr32-0961203313477227">32</xref></sup> Therefore, more research is needed also in this field.</p>
<p>Finally, few studies used brain imaging in depressed SLE patients. No correlation between brain abnormalities and depression have been found with brain magnetic resonance studies,<sup><xref ref-type="bibr" rid="bibr11-0961203313477227">11</xref></sup> while, on the contrary, SPECT analysis showed that depressed patients with SLE present cerebral blood flow reductions in discrete temporal and frontal regions that may account for depressive symptoms.<sup><xref ref-type="bibr" rid="bibr40-0961203313477227">40</xref></sup> Further research is also needed in this field. To date, psychological factors have resulted to be one of the most common causes to which depression could be attributed in SLE.</p>
</sec>
</sec>
<sec id="sec11-0961203313477227" sec-type="conclusions"><title>Conclusion</title>
<p>Depression and depressive disorders are very common in SLE, but so far important methodological limitations are present in the available literature and definitive point prevalence is difficult to determine. Further studies are needed to understand the type of depression, subset of symptoms, impact of suicide ideation and relation to SLE disease activity. Among the hypotheses on the possible mechanisms underlining the high association between depression and SLE, psychosocial factors were found to be the most frequently reported. The development of evidence-based guidelines is needed to improve the diagnosis of depression complications in SLE. Identification of lupus-specific biomarkers of depression is a high priority. Due to the high prevalence of depression in SLE and significant suicide risk of SLE psychiatric syndromes, systematic assessment to provide prompt diagnosis and adequate care should be a critical part of SLE patients' evaluation protocol, and universally accepted and validated evaluating tools should be established and introduced into clinical practice, as well as widely experienced therapeutic strategies.</p>
<p>High priority should also be given to the identification of SLE-specific biomarkers of depression.</p>
</sec>
</body>
<back>
<sec id="sec12-0961203313477227"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec13-0961203313477227"><title>Conflict of interest</title>
<p>All authors report no financial or other relationships relevant to the subject of this paper.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477227"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Sebastiani</surname><given-names>GD</given-names></name><name><surname>Gil</surname><given-names>A</given-names></name><name><surname>Lavilla</surname><given-names>P</given-names></name></person-group>. <article-title>Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients</article-title>. <source>Medicine</source> <year>2003</year>; <volume>82</volume>: <fpage>299</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr2-0961203313477227"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Tani</surname><given-names>C</given-names></name><name><surname>Aringer</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies</article-title>. <source>Ann Rheum Dis</source> <year>2010</year>; <volume>69</volume>: <fpage>1269</fpage>–<lpage>1274</lpage>.</citation></ref>
<ref id="bibr3-0961203313477227"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Tani</surname><given-names>C</given-names></name><name><surname>Carli</surname><given-names>L</given-names></name><name><surname>Bombardieri</surname><given-names>S</given-names></name></person-group>. <article-title>Glucocorticoids in systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>2011</year>; <volume>29</volume>: <fpage>S126</fpage>–<lpage>S129</lpage>.</citation></ref>
<ref id="bibr4-0961203313477227"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Govoni</surname><given-names>M</given-names></name><name><surname>Tomietto</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>485</fpage>–<lpage>492</lpage>.</citation></ref>
<ref id="bibr5-0961203313477227"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>A</given-names></name><name><surname>Kao</surname><given-names>AH</given-names></name></person-group>. <article-title>Neuropsychiatric systemic lupus erythematosus</article-title>. <source>Curr Neuropharmacol</source> <year>2011</year>; <volume>9</volume>: <fpage>449</fpage>–<lpage>457</lpage>.</citation></ref>
<ref id="bibr6-0961203313477227"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meszaros</surname><given-names>ZS</given-names></name><name><surname>Perl</surname><given-names>A</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group>. <article-title>Psychiatric symptoms in systemic lupus erythematosus: A systematic review</article-title>. <source>J Clin Psychiatry</source> <year>2012</year>; <volume>73</volume>: <fpage>993</fpage>–<lpage>1001</lpage>.</citation></ref>
<ref id="bibr7-0961203313477227"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feinglass</surname><given-names>EJ</given-names></name><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Dorsch</surname><given-names>CA</given-names></name><name><surname>Zizic</surname><given-names>TM</given-names></name><name><surname>Stevens</surname><given-names>MB</given-names></name></person-group>. <article-title>Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease</article-title>. <source>Medicine</source> <year>1976</year>; <volume>55</volume>: <fpage>323</fpage>–<lpage>339</lpage>.</citation></ref>
<ref id="bibr8-0961203313477227"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaposi</surname><given-names>EA</given-names></name></person-group>. <article-title>Neue Beitragäzur Kenntnis des Lupus erythematosus</article-title>. <source>Arch Dermatol Syph</source> <year>1872</year>; <volume>4</volume>: <fpage>36</fpage>–<lpage>78</lpage>.</citation></ref>
<ref id="bibr9-0961203313477227"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kassan</surname><given-names>SS</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name></person-group>. <article-title>Central nervous system lupus erythematosus. The need for classification</article-title>. <source>Arthritis Rheum</source> <year>1979</year>; <volume>22</volume>: <fpage>1382</fpage>–<lpage>1385</lpage>.</citation></ref>
<ref id="bibr10-0961203313477227"><label>10</label><citation citation-type="journal"><collab>ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature</collab>. <article-title>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>599</fpage>–<lpage>608</lpage>.</citation></ref>
<ref id="bibr11-0961203313477227"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>L</given-names></name><name><surname>Ron</surname><given-names>MA</given-names></name><name><surname>Ormerod</surname><given-names>IEC</given-names></name><name><surname>David</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DH</given-names></name><name><surname>Logsdail</surname><given-names>SJ</given-names></name></person-group>. <article-title>Psychiatric and neurological manifestations in systemic lupus erythematosus</article-title>. <source>Q J Med</source> <year>1988</year>; <volume>66</volume>: <fpage>27</fpage>–<lpage>38</lpage>.</citation></ref>
<ref id="bibr12-0961203313477227"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iverson</surname><given-names>GL</given-names></name></person-group>. <article-title>Psychopathology associated with systemic lupus erythematosus: A methodological review</article-title>. <source>Semin Arthritis Rheum</source> <year>1993</year>; <volume>22</volume>: <fpage>242</fpage>–<lpage>251</lpage>.</citation></ref>
<ref id="bibr13-0961203313477227"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wekking</surname><given-names>EM</given-names></name></person-group>. <article-title>Psychiatric symptoms in systemic lupus erythematosus: An update</article-title>. <source>Psychosom Med</source> <year>1993</year>; <volume>55</volume>: <fpage>219</fpage>–<lpage>228</lpage>.</citation></ref>
<ref id="bibr14-0961203313477227"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miguel</surname><given-names>EC</given-names></name><name><surname>Pereira</surname><given-names>RMR</given-names></name><name><surname>Pereira</surname><given-names>CAB</given-names></name><name><surname>Baer</surname><given-names>L</given-names></name><name><surname>Gomes</surname><given-names>RE</given-names></name><name><surname>de Sa</surname><given-names>LC</given-names></name></person-group>. <article-title>Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients</article-title>. <source>Medicine</source> <year>1994</year>; <volume>73</volume>: <fpage>224</fpage>–<lpage>232</lpage>.</citation></ref>
<ref id="bibr15-0961203313477227"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hugo</surname><given-names>FJ</given-names></name><name><surname>Halland</surname><given-names>AM</given-names></name><name><surname>Spangenberg</surname><given-names>JJ</given-names></name><name><surname>Whitelaw</surname><given-names>DA</given-names></name><name><surname>Rickman</surname><given-names>RC</given-names></name><name><surname>Hewlett</surname><given-names>RH</given-names></name></person-group>. <article-title>DSM-III-R classification of psychiatric symptoms in systemic lupus erythematosus</article-title>. <source>Psychosomatics</source> <year>1996</year>; <volume>37</volume>: <fpage>262</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr16-0961203313477227"><label>16</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>H</given-names></name></person-group>. <article-title>Psychopathology in the patient with lupus</article-title>. In: <person-group person-group-type="editor"><name><surname>Wallace</surname><given-names>DJ</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group> (eds.) <source>Dubois’ lupus erythematosus</source>, <edition>6th ed</edition>. <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott, Williams, &amp; Wilkins</publisher-name>, <year>1997</year>, pp. <fpage>75</fpage>–<lpage>82</lpage>.</citation></ref>
<ref id="bibr17-0961203313477227"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ainiala</surname><given-names>H</given-names></name><name><surname>Loukkola</surname><given-names>J</given-names></name><name><surname>Peltola</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus</article-title>. <source>Neurology</source> <year>2001</year>; <volume>57</volume>: <fpage>496</fpage>–<lpage>500</lpage>.</citation></ref>
<ref id="bibr18-0961203313477227"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brey</surname><given-names>RL</given-names></name><name><surname>Holliday</surname><given-names>SL</given-names></name><name><surname>Saklad</surname><given-names>AR</given-names></name><name><surname>Navarrete</surname><given-names>MG</given-names></name><name><surname>Hermosillo-Romo</surname><given-names>D</given-names></name><name><surname>Stallworth</surname><given-names>CL</given-names></name></person-group>. <article-title>Neuropsychiatric syndromes in lupus: prevalence using standardized definitions</article-title>. <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>1214</fpage>–<lpage>1220</lpage>.</citation></ref>
<ref id="bibr19-0961203313477227"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanna</surname><given-names>G</given-names></name><name><surname>Bertolaccini</surname><given-names>ML</given-names></name><name><surname>Cuadrado</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies</article-title>. <source>J Rheumatol</source> <year>2003</year>; <volume>30</volume>: <fpage>985</fpage>–<lpage>990</lpage>.</citation></ref>
<ref id="bibr20-0961203313477227"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Afeltra</surname><given-names>A</given-names></name><name><surname>Garzia</surname><given-names>P</given-names></name><name><surname>Mitterhofer</surname><given-names>AP</given-names></name><name><surname>Vadacca</surname><given-names>M</given-names></name><name><surname>Galluzzo</surname><given-names>S</given-names></name><name><surname>Del Porto</surname><given-names>F</given-names></name></person-group>. <article-title>Neuropsychiatric lupus syndromes — relationship with antiphospholipid antibodies</article-title>. <source>Neurology</source> <year>2003</year>; <volume>61</volume>: <fpage>108</fpage>–<lpage>110</lpage>.</citation></ref>
<ref id="bibr21-0961203313477227"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanly</surname><given-names>JG</given-names></name><name><surname>McCurdy</surname><given-names>G</given-names></name><name><surname>Fougere</surname><given-names>L</given-names></name><name><surname>Douglas</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>K</given-names></name></person-group>. <article-title>Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance</article-title>. <source>J Rheumatol</source> <year>2004</year>; <volume>31</volume>: <fpage>2156</fpage>–<lpage>2162</lpage>.</citation></ref>
<ref id="bibr22-0961203313477227"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachen</surname><given-names>LA</given-names></name><name><surname>Chesney</surname><given-names>MA</given-names></name><name><surname>Criswell</surname><given-names>LA</given-names></name></person-group>. <article-title>Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>61</volume>: <fpage>822</fpage>–<lpage>829</lpage>.</citation></ref>
<ref id="bibr23-0961203313477227"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nery</surname><given-names>FG</given-names></name><name><surname>Borba</surname><given-names>EF</given-names></name><name><surname>Viana</surname><given-names>VS</given-names></name><name><surname>Hatch</surname><given-names>JP</given-names></name><name><surname>Soares</surname><given-names>JC</given-names></name><name><surname>Bonfa</surname><given-names>E</given-names></name></person-group>. <article-title>Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with antiribosomal P antibodies</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> <year>2008</year>; <volume>32</volume>: <fpage>695</fpage>–<lpage>700</lpage>.</citation></ref>
<ref id="bibr24-0961203313477227"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Utset</surname><given-names>TO</given-names></name><name><surname>Golden</surname><given-names>M</given-names></name><name><surname>Siberry</surname><given-names>G</given-names></name><name><surname>Kiri</surname><given-names>N</given-names></name><name><surname>Crum</surname><given-names>RM</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>. <article-title>Depressive symptoms in patients with systemic lupus erythematosus: Association with central nervous system lupus and Sjogren's syndrome</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>2039</fpage>–<lpage>2045</lpage>.</citation></ref>
<ref id="bibr25-0961203313477227"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shortall</surname><given-names>E</given-names></name><name><surname>Isenberg</surname><given-names>D</given-names></name><name><surname>Newman</surname><given-names>SP</given-names></name></person-group>. <article-title>Factors associated with mood and mood disorders in SLE</article-title>. <source>Lupus</source> <year>1995</year>; <volume>4</volume>: <fpage>272</fpage>–<lpage>279</lpage>.</citation></ref>
<ref id="bibr26-0961203313477227"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>SE</given-names></name><name><surname>Smarr</surname><given-names>KL</given-names></name><name><surname>Parker</surname><given-names>JC</given-names></name><name><surname>Weidensaul</surname><given-names>DN</given-names></name><name><surname>Nelson</surname><given-names>W</given-names></name><name><surname>McMurray</surname><given-names>RW</given-names></name></person-group>. <article-title>Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</citation></ref>
<ref id="bibr27-0961203313477227"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Segui</surname><given-names>J</given-names></name><name><surname>Ramos-Casals</surname><given-names>M</given-names></name><name><surname>Garcia-Carrasco</surname><given-names>M</given-names></name><name><surname>De Flores</surname><given-names>T</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Valdes</surname><given-names>M</given-names></name></person-group>. <article-title>Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: A longitudinal study of active and inactive stages of the disease</article-title>. <source>Lupus</source> <year>2000</year>; <volume>9</volume>: <fpage>584</fpage>–<lpage>588</lpage>.</citation></ref>
<ref id="bibr28-0961203313477227"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muscal</surname><given-names>E</given-names></name><name><surname>Brey</surname><given-names>RL</given-names></name></person-group>. <article-title>Neurologic manifestations of systemic lupus erythematosus in children and adults</article-title>. <source>Neurol Clin</source> <year>2010</year>; <volume>28</volume>: <fpage>61</fpage>–<lpage>73</lpage>.</citation></ref>
<ref id="bibr29-0961203313477227"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>VH</given-names></name><name><surname>Gurland</surname><given-names>BJ</given-names></name><name><surname>Deming</surname><given-names>WE</given-names></name><name><surname>Fisher</surname><given-names>B</given-names></name></person-group>. <article-title>The study of the psychiatric symptoms of systemic lupus erythematosus. A biometric study</article-title>. <source>Psychosom Med</source> <year>1972</year>; <volume>3</volume>: <fpage>207</fpage>–<lpage>220</lpage>.</citation></ref>
<ref id="bibr30-0961203313477227"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Roger</surname><given-names>M</given-names></name><name><surname>Larson</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The psychosocial impact of systemic lupus erythematosus and rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source> <year>1984</year>; <volume>27</volume>: <fpage>13</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr31-0961203313477227"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>LC</given-names></name><name><surname>Lee</surname><given-names>T</given-names></name><name><surname>Boey</surname><given-names>M</given-names></name></person-group>. <article-title>Psychiatric manifestation of systemic lupus erythematosus in Singapore. A cross-cultural comparison</article-title>. <source>Br J Psychiatry</source> <year>1991</year>; <volume>159</volume>: <fpage>520</fpage>–<lpage>523</lpage>.</citation></ref>
<ref id="bibr32-0961203313477227"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magner</surname><given-names>MB</given-names></name></person-group>. <article-title>Psychiatric morbidity in outpatients with systemic lupus erythematosus</article-title>. <source>S Afr Med J</source> <year>1991</year>; <volume>80</volume>: <fpage>291</fpage>–<lpage>293</lpage>.</citation></ref>
<ref id="bibr33-0961203313477227"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stromberg</surname><given-names>R</given-names></name><name><surname>Wernering</surname><given-names>E</given-names></name><name><surname>Aberg-Wistedt</surname><given-names>A</given-names></name><name><surname>Furhoff</surname><given-names>AK</given-names></name><name><surname>Johansson</surname><given-names>SE</given-names></name><name><surname>Backlund</surname><given-names>LG</given-names></name></person-group>. <article-title>Screening and diagnosing depression in women visiting GPs' drop in clinic in Primary Health Care</article-title>. <source>BMC Fam Pract</source> <year>2008</year>; <volume>9</volume>: <fpage>34</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr34-0961203313477227"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawro</surname><given-names>T</given-names></name><name><surname>Krupińska-Kun</surname><given-names>M</given-names></name><name><surname>Rabe-Jabłońska</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Psychiatric disorders in patients with systemic lupus erythematosus: association of anxiety disorder with shorter disease duration</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>31</volume>: <fpage>1387</fpage>–<lpage>1391</lpage>.</citation></ref>
<ref id="bibr35-0961203313477227"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zakeri</surname><given-names>Z</given-names></name><name><surname>Shakiba</surname><given-names>M</given-names></name><name><surname>Narouie</surname><given-names>B</given-names></name><name><surname>Mladkova</surname><given-names>N</given-names></name><name><surname>Ghasemi-Rad</surname><given-names>M</given-names></name><name><surname>Khosravi</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience</article-title>. <source>Rheumatol Int</source> <year>2012</year>; <volume>32</volume>: <fpage>1179</fpage>–<lpage>1187</lpage>.</citation></ref>
<ref id="bibr36-0961203313477227"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>LF</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Pan</surname><given-names>HF</given-names></name><etal/></person-group>. <article-title>Prevalence and correlates of suicidal ideation in SLE inpatients: Chinese experience</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>32</volume>: <fpage>2707</fpage>–<lpage>2714</lpage>.</citation></ref>
<ref id="bibr37-0961203313477227"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneebaum</surname><given-names>AB</given-names></name><name><surname>Singleton</surname><given-names>JD</given-names></name><name><surname>West</surname><given-names>SG</given-names></name><etal/></person-group>. <article-title>Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus</article-title>. <source>Am J Med</source> <year>1991</year>; <volume>90</volume>: <fpage>54</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr38-0961203313477227"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eber</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Anti-ribosomal P-protein and its role in psychiatric manifestations of systemic lupus erythematosus: myth or reality?</article-title> <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>571</fpage>–<lpage>575</lpage>.</citation></ref>
<ref id="bibr39-0961203313477227"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandman-Goddard</surname><given-names>G</given-names></name><name><surname>Chapman</surname><given-names>J</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome</article-title>. <source>Semin Arthritis Rheum</source> <year>2007</year>; <volume>36</volume>: <fpage>297</fpage>–<lpage>315</lpage>.</citation></ref>
<ref id="bibr40-0961203313477227"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giovacchini</surname><given-names>G</given-names></name><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Manca</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Cerebral blood flow in depressed patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>1844</fpage>–<lpage>1851</lpage>.</citation></ref>
</ref-list>
</back>
</article>